A Study of Pyridostigmine in Postural Tachycardia Syndrome

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Feb 2026 to Feb 2027v30
  2. Site contact updatedv29
  3. Primary and study completion dates: Feb 2025 to Feb 2026v28
  4. Primary and study completion dates: Feb 2024 to Feb 2025v27
  5. Phase: Not applicable to Phase 2
    • Primary and study completion dates: Feb 2023 to Feb 2024
    • Collaborator revised
    v26
Show 24 earlier versionsHide 24 earlier versions
  1. Primary and study completion dates: Feb 2022 to Feb 2023v25
  2. Primary and study completion dates: Feb 2021 to Feb 2022v24
  3. Primary and study completion dates: Feb 2020 to Feb 2021v23
  4. Primary and study completion dates: Feb 2019 to Feb 2020v22
  5. Re-verified, no change to tracked fieldsv21
  6. Primary and study completion dates: Feb 2017 to Feb 2019v20
  7. Primary and study completion dates: Feb 2016 to Feb 2017v19
  8. Re-verified, no change to tracked fieldsv18
  9. Primary and study completion dates: Feb 2015 to Feb 2016v17
  10. Re-verified, no change to tracked fieldsv16
  11. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v15
  12. Primary and study completion dates: Oct 2013 to Feb 2015v14
  13. Primary and study completion dates: Oct 2012 to Oct 2013v13
  14. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v12
  15. Primary and study completion dates: Oct 2011 to Oct 2012v11
  16. Re-verified, no change to tracked fieldsv10
  17. Primary and study completion dates: Oct 2010 to Oct 2011v9
  18. Re-verified, no change to tracked fieldsv8
  19. Interventions: pyridostigmine (Drug) to Placebo (Drug), pyridostigmine (Drug)
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study arms: 0 to 2
    v7
  20. Primary completion date: Oct 2010
    • Study completion date: Oct 2009 to Oct 2010
    v6
  21. Eligibility criteria expanded, about 16 words
    • Study description shortened, about 34 words
    v5
  22. Eligibility criteria revisedv4
  23. Primary endpoint revised
    • Eligibility criteria expanded, about 3 words
    v3
  24. Eligibility criteria expanded, about 56 words
    • Site contact updated
    • Study title shortened, about 1 word
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mayo Clinic
1,027 trials monitored
See 130 trials at risk
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
Trial Details
NCT Number NCT00409435
Lead Sponsor Mayo Clinic
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS)
Conditions
(from sponsor)		 Postural Tachycardia Syndrome
Related terms Postural Orthostatic Tachycardia Syndrome
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov